Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsAll products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Cytomegalovirus (CMV) is a member of the herpes virus group which includes herpes simplex virus types 1 and 2; Varicella Zoster Virus, which causes chicken pox; and Epstein Barr virus, which causes infectious mononucleosis. These viruses remain dormant within the body over a long period. In humans, CMV is known as HCMV or human herpesvirus 5 (HHV-5). HHV-5 causes only a brief mononeucleosis-like malaise in immunocompetent adults, but may cause severe illness or death in immunosuppressed individuals. CMV pp65 is the early-late lower matrix phosphoprotein of CMV that may be relevant to the etiopathogenesis of scleroderma. CMV pp65 is a major constituent of the CMV virion bodies and is abundantly synthesized during lytic infection. In addition, the CMV pp65 protein is a frequent target for the exceptionally strong CMV-specific CD8(+) T cell response.
Loading...
| CAT | Product Name | Target Species | TCR Clone | Host Species | Epitope | Allele | Vector Type | Inquiry & Datasheet |
| TCR-C419 | Human anti-pp65 T cell receptor (CB-C159), pCDTCR1 | CMV | CB-C159 | Human | NLVPMVATV | HLA-A*02 | Lentiviral vector | |
| TCR-C420 | Human anti-pp65 T cell receptor (CB-C160), pCDTCR1 | CMV | CB-C160 | Human | NLVPMVATV | HLA-A*02 | Lentiviral vector | |
| TCR-C421 | Human anti-pp65 T cell receptor (CB-C161), pCDTCR1 | CMV | CB-C161 | Human | NLVPMVATV | HLA-A*02 | Lentiviral vector | |
| TCR-C422 | Human anti-pp65 T cell receptor (CB-C162), pCDTCR1 | CMV | CB-C162 | Human | NLVPMVATV | HLA-A*02 | Lentiviral vector | |
| TCR-C423 | Human anti-pp65 T cell receptor (CB-C163), pCDTCR1 | CMV | CB-C163 | Human | NLVPMVATV | HLA-A*02 | Lentiviral vector | |
| TCR-C424 | Human anti-pp65 T cell receptor (CB-C164), pCDTCR1 | CMV | CB-C164 | Human | NLVPMVATV | HLA-A*02 | Lentiviral vector | |
| TCR-C425 | Human anti-pp65 T cell receptor (CB-C165), pCDTCR1 | CMV | CB-C165 | Human | NLVPMVATV | HLA-A*02 | Lentiviral vector | |
| TCR-C426 | Human anti-pp65 T cell receptor (CB-C166), pCDTCR1 | CMV | CB-C166 | Human | NLVPMVATV | HLA-A*02 | Lentiviral vector | |
| TCR-C427 | Human anti-pp65 T cell receptor (CB-C167), pCDTCR1 | CMV | CB-C167 | Human | NLVPMVATV | HLA-A*02 | Lentiviral vector | |
| TCR-C428 | Human anti-pp65 T cell receptor (CB-C168), pCDTCR1 | CMV | CB-C168 | Human | NLVPMVATV | HLA-A*02 | Lentiviral vector | |
| TCR-C429 | Human anti-pp65 T cell receptor (CB-C169), pCDTCR1 | CMV | CB-C169 | Human | NLVPMVATV | HLA-A*02 | Lentiviral vector | |
| TCR-C430 | Human anti-pp65 T cell receptor (CB-C170), pCDTCR1 | CMV | CB-C170 | Human | NLVPMVATV | HLA-A*02 | Lentiviral vector | |
| TCR-C431 | Human anti-pp65 T cell receptor (CB-C171), pCDTCR1 | CMV | CB-C171 | Human | NLVPMVATV | HLA-A*02 | Lentiviral vector | |
| TCR-C432 | Human anti-pp65 T cell receptor (CB-C172), pCDTCR1 | CMV | CB-C172 | Human | NLVPMVATV | HLA-A*02 | Lentiviral vector | |
| TCR-C433 | Human anti-pp65 T cell receptor (CB-C173), pCDTCR1 | CMV | CB-C173 | Human | NLVPMVATV | HLA-A*02 | Lentiviral vector | |
| TCR-C434 | Human anti-pp65 T cell receptor (CB-C174), pCDTCR1 | CMV | CB-C174 | Human | NLVPMVATV | HLA-A*02 | Lentiviral vector | |
| TCR-C435 | Human anti-pp65 T cell receptor (CB-C175), pCDTCR1 | CMV | CB-C175 | Human | NLVPMVATV | HLA-A*02 | Lentiviral vector | |
| TCR-C436 | Human anti-pp65 T cell receptor (CB-C176), pCDTCR1 | CMV | CB-C176 | Human | NLVPMVATV | HLA-A*02 | Lentiviral vector | |
| TCR-C437 | Human anti-pp65 T cell receptor (CB-C177), pCDTCR1 | CMV | CB-C177 | Human | NLVPMVATV | HLA-A*02 | Lentiviral vector | |
| TCR-C438 | Human anti-pp65 T cell receptor (CB-C178), pCDTCR1 | CMV | CB-C178 | Human | NLVPMVATV | HLA-A*02 | Lentiviral vector |
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
